Use of Fresh Frozen Plasma and Plasma Proteins in Newborn Infants

Published: June 9, 2009
Abstract Views: 282
PDF: 7194
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Clinically significant hemorrhage, especially intracranial hemorrhage, is a major cause of morbidity and mortality in extremely preterm infants and is a rare event in otherwise healthy term infants. Infusions of FFP in newborn infants is effective in reducing blood loss associated with extracorporeal membrane oxygenation or cardiopulmonary bypass and to treat active bleeding due to disseminated intravascular coagulation, liver failure or vitamin K deficiency. However, routine use of fresh frozen plasma (FFP) in sick preterm infants for volume expansion, to treat coagulopathy in the absence of bleeding, or for partial exchange transfusion does not decrease mortality or morbidity.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Manco-Johnson, M., & Goldenberg, N. (2009). Use of Fresh Frozen Plasma and Plasma Proteins in Newborn Infants. Hematology Meeting Reports (formerly Haematologica Reports), 2(10). https://doi.org/10.4081/hmr.v2i10.455